Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2/PHASE3

Total Enrollment

372 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Study Completion Date

2016-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Due to limited experience with cabazitaxel in TCCU, the study will be started as a randomised phase II study. The aim of the phase II study is to evaluate if the response rates (CR + PR) are sufficiently high to further study the treatment regimens in a phase III setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03170960

Urothelial Carcinoma Renal Cell Carcinoma Non-Small Cell Lung Cancer +11 more

ACTIVE_NOT_RECRUITING PHASE1

Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours

NCT01581060

Advanced Solid Tumours

TERMINATED PHASE1/PHASE2

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

NCT06150664

Non Small Cell Lung Cancer Triple Negative Breast Cancer Hodgkin Lymphoma +2 more

RECRUITING PHASE1

A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)

NCT01600339

Urothelial Carcinoma

COMPLETED PHASE2

Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors

NCT00877474

ADVANCED SOLID TUMORS

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Once it is confirmed that the subjects fulfil the eligibility criteria and have signed the informed consent, they will be randomised to receive treatment based on cabazitaxel or vinflunine according to the following study schema:

(Randomize 1:1)

* Cabazitaxel 25 mg/m2 q3w
* Vinflunine 250-320 mg/m2 q3w

Random assignment of treatment will be stratified by the presence of 0 versus 1 of the following unfavourable prognostic risk factors proposed recently by Bellmunt et al. (1):

* Eastern Cooperative Oncology Group (ECOG) PS 1.
* Anaemia with Hb \<10 g/dL.
* Presence of liver metastases.

All patients enrolled in the study will receive a cycle of treatment with the study medication (cabazitaxel or vinflunine) every 21 days until disease progression or intolerable/unacceptable toxicity. Tumour evaluations will be scheduled every 6 weeks until progression

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urothelium Transitional Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cabazitaxel

Cabazitaxel 25 mg/m2 q3w. Cabazitaxel will be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion

Group Type EXPERIMENTAL

Cabazitaxel

Intervention Type DRUG

Cabazitaxel, to be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion.

Vinflunine

• Vinflunine will be given intravenously once every 21 days, starting at a dose of:

* 320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation
* 280 mg/m2 in patients aged \>75 - ≤80 years, and/or with PS 1 and/or prior pelvic radiation,
* 250 mg/m2 in patients aged \>80 years.

Group Type ACTIVE_COMPARATOR

Vinflunine

Intervention Type DRUG

Vinflunine, to be given intravenously once every 21 days, as a 20 minute intravenous infusion, starting at a dose of:

* 320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation, and of
* 280 mg/m2 in patients aged \>75 - ≤80 years or with PS 1 or prior pelvic radiation,
* 250 mg/m2 in patients aged \>80 years.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cabazitaxel

Cabazitaxel, to be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion.

Intervention Type DRUG

Vinflunine

Vinflunine, to be given intravenously once every 21 days, as a 20 minute intravenous infusion, starting at a dose of:

* 320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation, and of
* 280 mg/m2 in patients aged \>75 - ≤80 years or with PS 1 or prior pelvic radiation,
* 250 mg/m2 in patients aged \>80 years.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Jevtana Javlor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent
* Histologically confirmed TCCU (urinary bladder, urethra, ureter or renal pelvis). Patients with mixed histology may be enrolled if TCCU is the predominant component (i.e., \> 50% of the histopathology sample) with the exception of neuroendocrine or small cell carcinoma.
* Advanced disease defined as a locally advanced tumour considered unresectable (T4b), node involvement in the inguinal area or above the aortic bifurcation (that are considered to be distant nodes and so metastasis) or metastasis in distant organs.
* Patient should have received one prior platinum-based chemotherapy treatment for locally advanced or stage IV TCCU. Prior platinum-based adjuvant or neoadjuvant therapy is allowed if more than 6 months have elapsed since the end of adjuvant or neoadjuvant therapy till tumour relapse.
* At least one measurable tumour lesion (measurable disease, as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria v1.1
* ≥18 years.
* ECOG PS 0 or 1.
* May have no more than ONE of the following unfavourable risk factors:

1. haemoglobin \<10 g/dL
2. presence of liver metastasis
3. ECOG PS 1
* Life expectancy of at least 12 weeks.
* Adequate hematologic, hepatic, and renal function, defined by:
* Females of childbearing potential must have a negative serum pregnancy test within 7 days of study entry.

Exclusion Criteria

* Patients that have 2 or more of the following unfavourable risk factors:

1. Haemoglobin \<10 g/L
2. Liver metastasis
3. ECOG PS 1.
* Women who are currently pregnant or breast-feeding.
* Any unresolved non-hematologic Adverse Event (AE) grade \>1 (Common Toxicity Criteria for Adverse Effects (NCI-CTCAE) Version 4.0) from previous anti-cancer therapy (other than alopecia)
* Patients who had undergone major surgery, radiation therapy or treatment with chemotherapy or any investigational agent within 28 days prior to Study day 1.
* Evidence of severe or uncontrolled systemic disease or any concurrent condition
* History of another neoplasm.
* History of hypersensitivity reactions to taxanes (docetaxel) (cabazitaxel specific criteria), vinca alkaloids (vinflunine specific criteria) or to any of the formulation excipients, including polysorbate 80
* clear evidence or symptoms of central nervous system metastasis (cabazitaxel specific criteria).
* Clinically significant cardiac condition

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No